Book a Meeting

Anti-S1P Antibody, Non-Fucosylated (BioBet-436ZP) (CAT#: BioBet-436ZP) Datasheet

Target
S1P
Isotype
IgG
Description
Anti-S1P Antibody, Non-Fucosylated (BioBet-436ZP) is a humanized monoclonal IgG antibody against S1P. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced S1P antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
S1P
Alternative Names
Sonepcizumab; LT1009; humanized Sphingomab; Sphingosine-1-phosphate; S1P
Cellular Localization
Plasma membrane, Endosome
Involvement in Disease
Diseases associated with S1PR1 include Autoimmune Encephalitis and Second-Degree Atrioventricular Block.
Related Pathways
Its related pathways are Signaling by GPCR and Signaling events mediated by VEGFR1 and VEGFR2.
Function
The biological activity of the G protein-coupled receptor, the lysophospholipid sphingosine 1-phosphate (S1P), appears to be a coupled G(i) subclass isoform G protein. Signal transduction leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, possibly through its role in the formation of lip flaps under the stimulation of actin cytoskeleton reorganization and enhanced sphingosine kinase SPHK1 activity. Required for normal chemotaxis of sphingosine 1-phosphate. This is necessary for normal embryonic heart development and heart morphology. It plays an important role in the regulation of budding, angiogenesis and vascular maturation. Inhibit angiogenesis and prevent excessive angiogenesis during blood vessel development. This is necessary for the normal discharge of mature T cells from the thymus into the bloodstream and surrounding lymphatic organs. Participate in the migration of osteoclast precursor cells, regulate bone mineralization and bone homeostasis (similar). It plays a role in the response of lung endothelial cells to oxidized 1-palmitoyl-2-arachidonic-sn-glycerol-3-phosphocholine and the protection of lung injury induced by ventilator.
Post-translational modifications
S1P-induced endothelial cell migration requires the PKB/AKT1-mediated phosphorylation of the third intracellular loop at the Thr-236 residue.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-436ZP
Host
Humanized
Species Reactivity
Human
Description
ADCC-enhanced Sonepcizumab is a non-fucosylated anti-S1P therapeutic biobetter antibody.

Related Products

Anti-S1P Antibody, Highly Galactosylated (BioBet-GA-436ZP) (CAT#: BioBet-GA-436ZP)
Anti-S1P Antibody, Half-Life Extended (AES-0622-ZP1210) (CAT#: AES-0622-ZP1210)
Anti-S1P Antibody, Recycling (AES-0622-ZP226) (CAT#: AES-0622-ZP226)
Anti-S1P Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP554) (CAT#: AES-0622-ZP554)
Anti-S1P Antibody, On-Target (AES-0622-ZP882) (CAT#: AES-0622-ZP882)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.